Original Research

High Rates of Vitamin D Deficiency in Acute Rehabilitation Patients

Jennifer Wu, MD, PhD a,b, Valerie Chavez-Arom, MD a, Jay J. Han, MD a, Bi-Ying Yeh, MD a

a Department of Physical Medicine and Rehabilitation, University of California, Irvine Medical Center, Orange, CA
b Department of Pediatric Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA

Abstract

Objective: To determine the prevalence of low vitamin D (<30 ng/mL), including vitamin D insufficiency (20-29.9 ng/mL) and deficiency (<20 ng/mL), in an acute rehabilitation setting.

Design: Cross-sectional, retrospective cohort study.

Setting: University-affiliated inpatient rehabilitation facility (IRF) at a metropolitan county hospital.

Participants: Patients (N=100; 64 men/36 women), aged 19-92 years (mean, 62±18.9y), who were admitted to and discharged from an IRF over a 6-month study period. The most frequent admitting diagnoses included stroke (n=11), brain injury (n=36), spinal cord injury (n=14), and polytrauma (n=10).

Interventions: Not applicable.

Main Outcome Measures: Serum vitamin-25 (OH)D level at admission to the IRF.

Results: Of 100 patients, 76% had low vitamin D (<30 ng/mL), with 29% demonstrating vitamin D insufficiency (20-29.9 ng/mL) and 47% demonstrating vitamin D deficiency (<20 ng/mL). Younger patients demonstrated higher rates of vitamin D deficiency compared with older patients (P<.0001).

Conclusions: Low vitamin D is common in patients admitted to the IRF, with rates more than double those reported in the general population among individuals younger than 45 years. The current results suggest that the IRF setting may be a favorable checkpoint to screen for and initiate treatment of low vitamin D and optimize rehabilitation outcomes.

© 2021 The Authors. Published by Elsevier Inc. on behalf of American Congress of Rehabilitation Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Vitamin D is an essential mediator of calcium metabolism throughout the body. Although the association between vitamin D, bone health, and fracture risk is well known, vitamin D status also has implications in wide-ranging systems beyond the skeletal system. Low vitamin D (<30 ng/mL) has been associated with increased risk of cardiovascular disease, malignancy, depression, and autoimmune diseases. In addition to fracture risk, low vitamin D is associated with increased risk of progression in musculoskeletal pain and decreased muscle strength.

Recent studies report the reemergence of vitamin D deficiency as a global health concern. Among the general population, global rates of vitamin D deficiency in healthy adults range from 1%-80%. In the United States, a large scale study of community-dwelling adults reported rates of vitamin D deficiency as high as 41%, with the highest rates noted in African American individuals; Hispanic individuals; individuals without college education; and those who are obese, have hypertension, have low high-density lipoprotein levels, and are in poor health.

The inpatient rehabilitation patient has multiple risk factors for low vitamin D, including cardiovascular disease, hypertension, diabetes, and malignancy. Compared with patients discharged directly to home, inpatient rehabilitation patients are older, have more medical comorbidities, and have more functional deficits, including decreased mobility. Given a previous study suggesting that vitamin D supplementation reduced the risk of falls in institutionalized individuals, the inpatient rehabilitation setting is potentially a prime juncture to recognize and treat functionally relevant low vitamin D.

Previous studies evaluating the rates of low vitamin D in the acute rehabilitation setting are limited. The current study examined rates of low vitamin D (<30 ng/mL), including vitamin D insufficiency (20-29.9 ng/mL) and deficiency (<20 ng/mL) in an acute rehabilitation setting at a metropolitan academic medical center. Secondary analyses evaluated associations between vitamin D status, demographic and clinical variables (age, sex, ethnicity, admitting diagnosis, presence of fractures, treatment with antiepileptics, treatment with systemic steroids).

In line with clinical practice guidelines published by the Endocrine Society in 2011, patients who were vitamin D deficient (<20 ng/mL) were treated with 50,000 IU of vitamin D2 once a week for 8 weeks, with instructions to follow up with a primary care provider after discharge. During the study period, oral vitamin D supplementation was well tolerated, and no adverse effects were identified or reported.

**Measurements**

Vitamin D status was determined from blood serum levels of total serum 25(OH)D using an immunoassay. The lower limit of the immunoassay for serum vitamin D was 7. For patients in whom vitamin D levels were undetectable, a value of 7 was assigned for statistical calculations. Calcium, phosphorus, and magnesium levels were also determined from blood serum samples. Reference ranges are provided in table 1.

**Data analysis**

Bivariate analyses between vitamin D level and continuous variables (age, BMI, pre-IRF length of acute hospitalization) were performed using 2-tailed linear regression models. Analyses between vitamin D level and categorical variables (sex, ethnicity, admitting diagnosis, presence of fractures, treatment with antiepileptics, treatment with systemic steroids) were performed using 1-way analysis of variance. Analyses between vitamin D level and categorical variables were performed using the chi-square test. Parametric statistical methods were used because all measures were normally distributed or could be transformed to a normal distribution. Statistical significance was set at \( P < .05 \), with Bonferroni correction for multiple comparisons. Statistical tests were performed using R, version 3.6.1.

| Table 1 Reference ranges for serum 25(OH)D, calcium, phosphorus, and magnesium |
|---------------------------------|----------|----------|
| **Serum Measurement**           | **Lower Limit** | **Upper Limit** |
| 25-OH vitamin D, ng/mL          |          |          |
| Sufficient                       | 30.0     | 100.0    |
| Insufficient                     | 20.0     | 29.9     |
| Deficient                        | 19.9     |          |
| Calcium, mg/dL                   | 8.6      | 10.3     |
| Magnesium, mg/dL                 | 1.9      | 2.7      |
| Phosphorus, mg/dL                | 2.5      | 5.0      |
Results

Study cohort

A total of 115 unique patients were admitted to IRF during the study period. Nine patients did not have vitamin D levels as part of admission labs owing to insufficient specimen or systematic errors in admission orders. Of the remaining 106 patients, 6 were already receiving vitamin D supplementation either as part of home medications or as part of treatment initiated during the acute hospitalization. Excluding patients who did not have admission vitamin D level (n=9) and those already receiving vitamin D supplementation prior to IRF admission (n=6), the subsequent study sample included 100 patients (from 115 contiguous and unique patients admitted and with 15 excluded from study). The study cohort was aged 19-92 years with a mean age of 62.0±18.9 years; 36% were women. Demographic and clinical characteristics of the study sample are provided in Table 2.

Vitamin D status

The study sample had a mean vitamin D level of 24.6±13.8 ng/mL. In total, 76 individuals demonstrated low vitamin D levels (<30 ng/mL), with 47 in the deficient (<20 ng/mL) range and 29 in the insufficient (20-29.9 ng/mL) range. Three individuals had undetectable levels of serum 25(OH)D (<7 ng/mL).

Age was associated with vitamin D status

There was a statistically significant association between age and low vitamin D (<30 ng/mL; t=5.46; P<.0001). There was also a statistically significant association between younger age and higher rates of vitamin D deficiency (<20 ng/mL; t=4.12; P<.0001). When the study sample was subdivided into 5 contiguous age subgroups, vitamin D deficiency was proportionally higher in younger subgroups compared with older subgroups (fig 1).

| Characteristic | 25 (OH)D <30 ng/mL | 25 (OH)D ≥30 ng/mL | P Value |
|----------------|------------------|------------------|--------|
| Age, mean ± SD | 58.0±19.2 | 74.8±10.6 | <.0001 |
| <31 y, n (%) | 10 (100) | 0 | |
| 31-45 y, n (%) | 12 (100) | 0 | |
| 46-60 y, n (%) | 11 (79) | 3 (21) | |
| 61-75 y, n (%) | 25 (76) | 8 (24) | |
| >75 y, n (%) | 18 (58) | 13 (42) | |
| Sex, n (%) | | | .25 |
| Female | 25 (69) | 11 (31) | |
| Male | 51 (80) | 13 (20) | |
| Ethnicity, n (%) | | | .73 |
| Non-Hispanic | 56 (76) | 18 (24) | |
| Hispanic | 19 (79) | 5 (21) | |
| BMI, mean ± SD | 26.0±6.0 | 26.5±6.9 | .73 |
| Admitting diagnosis, n (%) | | | .67 |
| Stroke | 11 (85) | 2 (15) | |
| TBI | 6 (67) | 3 (33) | |
| Nontraumatic brain injury | 15 (83) | 3 (17) | |
| Traumatic SCI | 2 (100) | 0 | |
| Nontraumatic SCI | 12 (67) | 6 (33) | |
| Other neurologic conditions* | 7 (70) | 3 (30) | |
| Other orthopedic conditions† | 3 (75) | 1 (25) | |
| Polytrauma with and without TBI | 10 (83) | 2 (17) | |
| Burn | 0 | 1 (100) | |
| Miscellaneous‡ | 10 (77) | 3 (23) | |
| Pre-IRF length of acute hospitalization, mean ± SD | 9.33±9.11 | 6.46±5.90 | .08 |
| Presence of acute fractures, n (%) | | | .08 |
| Yes | 19 (90) | 2 (10) | |
| No | 57 (72) | 22 (28) | |
| Treatment with antiepileptics, n (%) | | | .79 |
| Yes | 17 (74) | 6 (26) | |
| No | 59 (77) | 18 (23) | |
| Treatment with systemic steroids, n (%) | | | .18 |
| Yes | 11 (92) | 1 (8) | |
| No | 65 (74) | 23 (26) | |

Abbreviations: SCI, spinal cord injury; TBI, traumatic brain injury.

* Other neurologic conditions included multiple sclerosis (n=1), Parkinsonism (n=2), and neuromuscular disorders (n=1).
† Other orthopedic conditions included unilateral hip fracture (n=2).
‡ Miscellaneous conditions included cardiac disorders (n=4), debility (n=2), surgical complications (n=1), neoplasm (n=5), and infection (n=1).
Sex, ethnicity, BMI, admitting diagnosis, pre-IRF length of acute hospitalization, presence of acute fractures, treatment with antiepileptic medications (including levetiracetam, lamotrigine, and carbamazepine), and treatment with systemic steroids (including dexamethasone and prednisone) did not demonstrate statistically significant associations with vitamin D status ($P > .05$) (see table 2). Concurrent hypocalcemia, hypophosphatemia, hypomagnesemia, and hypermagnesemia were also not associated with low vitamin D ($< 30 \text{ ng/mL}$; $P > .05$). There was a statistical association between low vitamin D and hyperphosphatemia ($\chi^2 = 6.30; P = .012$), which did not survive Bonferroni correction.

**Multivitamin cotreatment**

Of the 100 patients included in the study sample, 19 individuals either reported taking multivitamins before acute hospital admission or were started on multivitamin treatment during the acute hospitalization prior to IRF admission. Compared with those not taking a multivitamin before IRF admission, there was not a statistically significant difference between groups with respect to rates of low ($< 30 \text{ ng/mL}$), insufficient (20-29.9 ng/mL), or deficient ($< 20 \text{ ng/mL}$) vitamin D. Furthermore, the groups did not differ with respect to pre-IRF length of acute hospitalization, age, sex, BMI, presence of fractures, treatment with antiepileptic medications, or treatment with systemic steroids. There was a statistical difference between groups with respect to ethnicity ($\chi^2 = 3.96; P < .05$), which did not survive Bonferroni correction.

**Discussion**

The current study evaluated the rates of low vitamin D in patients admitted to IRF. Overall, 76% of patients had low vitamin D ($< 30 \text{ ng/mL}$), with 47% in the deficient range ($< 20 \text{ ng/mL}$) and 29% in the insufficient range (20-29.9 ng/mL). Individuals who were younger were more likely to be vitamin D deficient, but other demographic and clinical covariates, including sex, BMI, hypocalcemia, hypophosphatemia, hypomagnesemia, presence of fractures, and treatment with systemic steroids were not significantly associated with low vitamin D.

There are limited previous studies evaluating rates of low vitamin D in an IRF setting. As per Kiebzak et al, $11\%$ of patients with stroke, acute fracture, and hip or knee replacement admitted to an inpatient rehabilitation unit were vitamin D deficient. Conversely, a group of patients admitted to a subacute rehabilitation facility were 49.1% vitamin D deficient, a rate similar to that described in the current report. Differences in reported rates of vitamin D deficiency likely reflect the changes in inpatient rehabilitation patient cohorts in response to federal regulatory changes affecting IRF reimbursement systems. As a result, the current acute rehabilitation patient is significantly less likely to be admitted after lower-limb joint replacement, as seen by Kiebzak et al (38 of 77 patients). In contrast, the current study describes a group with primarily neurologic disorders (including stroke, brain injury, and spinal cord injury) who required longer acute hospitalizations, suggesting that the current group represents a sicker and more functionally-debilitated inpatient rehabilitation cohort compared with that previously reported.
The current study is presented on the backdrop of recently updated recommendations on vitamin D deficiency screening in adults by the US Preventive Services Task Force. Although the Task Force currently recommends against population-based vitamin D deficiency screening in community-dwelling, nonpregnant adults, the recommendation statement also specifies that this recommendation excludes individuals who are hospitalized. The recommendation also excludes those with signs or symptoms of vitamin D deficiency, including muscle weakness, such as functionally impaired patients admitted to IRF. The supposition that vitamin D deficiency is related to degree of functional impairment is supported by previous studies demonstrating high rates of vitamin D in IRF patients admitted with neurologic diagnoses.

The functional implications of low vitamin D levels are underpinned by its association with overall musculoskeletal physiology. Low vitamin D (<30 ng/mL) has been shown to cause reversible proximal myopathy through type II fiber atrophy and decreased protein synthesis. Functionally, patients with low vitamin D demonstrate reduced grip strength, decreased lower extremity function, sarcopenia, and increased body sway. Together, impairments relating to low vitamin D result in increased risk of falls and decreased functional capacity. Indeed, in a US study of 4100 ambulatory older adults (age >60y), low vitamin D was shown to increase time to completion on the 8-foot walk test and the sit-to-stand test. Fortunately, the deleterious effects of low vitamin D on the musculoskeletal system are potentially reversible. In the osteoporotic and osteopenic patient population, calcium and vitamin D supplementation reduces fracture risk, whereas vitamin D supplementation in patients with hemiplegia poststroke was shown to accelerate balance recovery and improve overall functional capacity. Finally, a meta-analysis of individuals with a mean age >65 years receiving supplemental vitamin D found that both supplemental and active forms of vitamin D reduced fall risk by up to 26%.

The current study found that age was inversely associated with low vitamin D status, such that rates of vitamin D <30 ng/mL were 100% among those who were aged <45 years on IRF admission. Given that the half-life of vitamin D is approximately 2-3 weeks and that the average pre-IRF length of stay in the currently reported group was 9.33 days, low vitamin D in younger patients admitted to IRF after acute hospitalization is likely a premorbid condition. This finding is consistent with recent reports demonstrating surprisingly high rates of vitamin D deficiency among young adults, particularly those with central obesity. Furthermore, as demonstrated in the current group in which younger individuals were more likely to be admitted to IRF owing to polytrauma resulting in multiple acute fractures, these findings provide support for routine screening of vitamin D deficiency in younger individuals admitted to IRF for polytrauma.

Secondary measures, including ethnicity and BMI, did not correlate with vitamin D status. Prior reports have shown a higher incidence of low vitamin D (<30 ng/mL) in ethnic minorities compared with their White counterparts. In the current study, there was a trend demonstrating that Hispanic patients had a higher prevalence of low vitamin D compared with non-Hispanic patients. However, the association was not statistically significant and may reflect an oversimplification of the ethnicity classifications in the current study design. Although previous studies report associations between low vitamin D, adiposity, and obesity-related chronic diseases, the cohort demonstrating low vitamin D in the current study had an average BMI that did not fall within the obese range.

There were no observed differences in the prevalence of low vitamin D in patients receiving antiepileptic or steroid therapy. Long-term treatment with antiepileptics has been found to have negative effects on bone health including decreasing bone density, altering bone metabolism biochemically, modifying bone turnover markers, and increasing fracture risk, resulting in osteomalacia, hypocalcemia, hypophosphatemia, and decreased levels of vitamin D metabolites. In the current study, antiepileptic therapy was primarily administered for seizure prophylaxis in the setting of acute injury. As a result, the short duration of antiepileptic treatment combined with a relatively small patient cohort of patients receiving antiepileptic or steroid medication likely resulted in an underpowered analysis of the relationship between antiepileptic or steroid therapy and vitamin D status.

Study limitations

The current study design and results have multiple limitations. As a cross-sectional and retrospective study, the findings reported represent associations and not causal relationships. Future studies that include comparative analyses examining differences in vitamin D status between IRF patients and a matched cohort of healthy, community dwelling individuals are needed to determine rates of low vitamin D accounting for regional covariates, including latitude, ethnic diversity, and dietary supplementation. In addition, longitudinal studies are needed to determine the effect of vitamin D supplementation on risk of falls, fractures, and functional outcomes after IRF discharge; patient compliance with prescribed supplementation and follow-up care; as well as long-term side effects or adverse events associated with supplementation.

Conclusions

In a cohort of 100 patients admitted to an acute rehabilitation unit after acute care, the rate of low vitamin D (<30 ng/mL) was 76%, with 47% of patients demonstrating vitamin D deficiency (<20 ng/mL). The present report demonstrates high rates of vitamin D deficiency in the IRF setting and lends support toward classifying the inpatient rehabilitation patient as an at-risk population for vitamin D deficiency. As such, the IRF setting may be a prime juncture for identifying and initiating treatment for functionally relevant vitamin D deficiency.

Suppliers

a. Immunoassay; Beckman Coulter.
b. R, version 3.6.1; R Foundation for Statistical Computing.
Corresponding author

Jennifer Wu, MD, PhD, Spaulding Rehabilitation Hospital, 300 First Ave, Boston, MA 02129. E-mail address: jewu@partners.org.

Acknowledgment

We thank Shane Davis, MD, for assistance with data collection and patient care.

References

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
2. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010;106:963-8.
3. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-57.
4. Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry 2013;202:100-7.
5. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
6. Bener A, Alsaeed A, Al-Ali M, et al. High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children. Acta Diabetol 2009;46:183-9.
7. Bergink AP, Uitterlinden AG, Van Leeuwen JP, et al. Vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee: the Rotterdam Study. J Clin Rheumatol 2009;15:230-7.
8. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996;125:335-9.
9. Heath KM, Elovici EP. Vitamin D deficiency: implications in the rehabilitation setting. Am J Phys Med Rehabil 2006;85:916-23.
10. Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009;20:1807-20.
11. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol 2014;144:138-45.
12. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 2011;31:48-54.
13. Everink IH, van Haastrup JC, van Hoof SJ, Schols JM, Kempen GI. Factors influencing home discharge after inpatient rehabilitation of older patients: a systematic review. BMC Geriatr 2016;16:5.
14. Sari A, Durmus B, Karaman CA, Ogut E, Aktas I. A randomized, double-blind study to assess if vitamin D treatment affects the outcomes of rehabilitation and balance in hemiplegic patients. J Phys Ther Sci 2018;30:874-8.
15. von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Bulletin of the World Health Organization 2007;85:867-72.
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
17. Madenci OC, Orucu A, Yildiz Z, et al. Evaluation of new Beckman Coulter 25(OH) vitamin D assay and potential improvement of clinical interpretation. Biochem Med (Zagreb) 2017;27:332-41.
18. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
19. Kiebzak GM, Moore NL, Margolis S, Hollis B, Kervorkian CG. Vitamin D status of patients admitted to a hospital rehabilitation unit: relationship to function and progress. Am J Phys Med Rehabil 2007;86:435-45.
20. Shinchuk LM, Morse L, Huancahuari N, Arum S, Chen TC, Holick MF. Vitamin D deficiency and osteoporosis in rehabilitation inpatients. Arch Phys Med Rehabil 2006;87:904-8.
21. Medicare Payment Advisory Commission. Chapter 5: monitoring post-acute care. Available at: http://www.medpac.gov/docs/default-source/reports/chapter-5-monitoring-post-acute-care-june-2003-report-.pdf?sfvrsn=0. Accessed September 19, 2019.
22. US Preventive Services Task ForceKrist AH, Davidson KW, et al. Screening for vitamin D deficiency in adults: US Preventive Services Task Force recommendation statement. JAMA 2021;325:1436-42.
23. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986;7:434-48.
24. Visser M, Deeg DJ, Lips P. Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003;88:5766-72.
25. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr 2004;80:752-8.
26. Trivedi DP, Dool R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.
27. Weaver CM, Alexander DD, Boushey CJ, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 2016;27:367-76.
28. Weaver CM, Dawson-Hughes B, Lappe JM, Wallace TC. Erratum and additional analyses re: calcium plus vitamin D supplementation and the risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int 2016;27:2643-6.
29. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009;339:b3692.
30. AliQuaz AM, Kazi A, Fouda M, Alyousefi N. Age and gender differences in the prevalence and correlates of vitamin D deficiency. Arch Osteoporos 2018;13:49.
31. Liu X, Baylin A, Levy PD. Vitamin D deficiency and insufficiency among US adults: prevalence, predictors and clinical implications. Br J Nutr 2018;119:928-36.
32. Herrick KA, Storandt RJ, Afful J, et al. Vitamin D status in the United States, 2011-2014. Am J Clin Nutr 2019;110:150-7.
33. Weishaar T, Rajan S, Keller B. Weight and skin colour as predictors of vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996;125:335-9.
34. Rajan S, Weishaar T, Keller B. Weight and skin colour as predictors of vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996;125:335-9.
35. Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr 2003;3:91-5.